A. Tsuhako

发表

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Wei Xu, J. Nuss, Wentao Zhang, 2012, Bioorganic & medicinal chemistry letters.

Discovery of XL413, a potent and selective CDC7 inhibitor.

Wei Xu, Charles R. Holst, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

K. Morrissey, F. Hodi, M. Ahn, 2019, Clinical Cancer Research.

Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.

Wei Xu, D. J. Matthews, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases

J. Nuss, A. Tsuhako, N. Anand, 2009 .

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Wei Xu, D. J. Matthews, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.

Wei Xu, Wei Cheng, F. Yakes, 2012, Bioorganic & medicinal chemistry letters.

A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

K. Morrissey, F. Hodi, P. LoRusso, 2017 .

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

J. Berlin, M. Hidalgo, P. LoRusso, 2017, The oncologist.